Managing Myelosuppression in Small Cell Lung Cancer: The Case for Trilaciclib

Small cell lung cancer (SCLC) remains one of oncology's most challenging diseases to treat, in large part because of the significant hematopoietic toxicity associated with every available chemotherapy regimen. Whether patients receive platinum-etoposide in the first-line setting, lurbinectedin (Zepzelca) for maintenance or later lines, or agents such as docetaxel or topotecan, bone marrow suppression is a near-universal consequence.

"We haven't defined [SCLC] biologically very well, so the opportunities for targeted therapies are very limited," noted Martin Dietrich, MD, PhD, a medical oncologist with the US Oncology Network in Orlando, Florida, in an interview with Targeted Oncology, underscoring why chemotherapy remains the backbone of treatment—and why protecting patients from its toxicities is paramount.

Traditional strategies for managing myelosuppression—dose reductions, treatment delays, and granulocyte colony-stimulating factor (G-CSF) support—have long focused primarily on the neutrophil lineage. While G-CSF addresses bacterial infection risk, it leaves thrombocytopenia and anemia largely unmanaged. For patients with SCLC, who are typically older and carry significant cardiovascular and pulmonary comorbidities, the cumulative burden of all three cytopenias can be severe.

"The impact of anemia is exponential in a patient with a reduced cardiopulmonary capacity," Dietrich observed. "We oftentimes have patients with a hemoglobin of 9 or 10. We rarely ever effectively intervene."

Trilaciclib (Cosela), a CDK4/6 inhibitor, offers a biologically distinct approach to this problem. Its mechanism centers on CDK6-driven cell cycle progression in the hematopoietic compartment, where CDK6 regulates differentiation from the earliest hematopoietic stem cells through to fully mature blood cells. By transiently inhibiting CDK6 prior to chemotherapy, trilaciclib induces a nonproliferative state via the retinoblastoma protein (RB1), rendering hematopoietic stem cells resistant to chemotherapy-induced damage.

Crucially, this protective effect is selective: SCLC tumors are characterized by RB1 deficiency and thus remain unaffected by CDK6 inhibition, preserving full chemotherapeutic cytotoxicity against the cancer itself.

"While we are inhibiting CDK6, both in SCLC cells and the hematopoietic stem cell, it really only affects the hematopoietic stem cell with regards to suppression of proliferation," Dietrich explained.

Clinical trial data underscore the breadth of trilaciclib's myeloprotective effects. In placebo-controlled, first-line studies incorporating chemotherapy plus immunotherapy—the current standard of care for SCLC—the rate of severe neutropenia (absolute neutrophil count ≤500/µL) dropped from approximately 50% in the placebo arm to just 2% with trilaciclib. Comparable reductions were observed across platelet and red blood cell lineages.¹

"We see about 50% rate for severe neutropenia without trilaciclib. Now if we deploy trilaciclib in the intervention arm, this percentage goes down to 2%," Dietrich noted. Rates of anemia and severe anemia also decreased meaningfully, a benefit of particular importance given the limited options for managing chemotherapy-induced anemia in this population; erythropoiesis-stimulating agents are generally not appropriate in this context, and hemoglobin levels are often too high to warrant transfusion yet too low to avoid symptomatic impact.

Beyond laboratory values, trilaciclib translates to meaningful improvements in patient-reported outcomes. Preserved functional status and reduced fatigue measured by validated anemia-fatigue indices have been documented in trials. Fewer dose delays and reductions also streamline care delivery.

"If we have to give growth factors, we cannot give patients treatment for 48 to 72 hours—we would basically lose 3 or sometimes 5 days," Dietrich said, noting the downstream scheduling burdens on infusion units when cytopenias disrupt planned treatment cycles.

Looking ahead, the emergence of immunotherapy, including approved PD-L1 inhibitors and bispecific T-cell engagers such as tarlatamab (Imdelltra), adds another dimension to the rationale for comprehensive myeloprotection. Lymphopenia has been associated with worse outcomes in patients receiving immunotherapy, and preserving the lymphocyte pool alongside other hematopoietic lineages may support durable immunotherapy benefit.

"Preserving every aspect of the bone marrow is both a treatment-related factor and a durability-related factor," Dietrich said.

From a practical standpoint, trilaciclib is administered as a 30-minute intravenous infusion prior to chemotherapy and is generally well tolerated. It can be used concomitantly with G-CSF when warranted.

Dietrich emphasized its conceptual reframing: "This is not an active treatment; we use CDK4/6 inhibitors here in a very different intent. We have CDK4/6 inhibitors as therapeutics in breast cancer; here we're using them as a supportive care medication." In that light, trilaciclib may be best understood not as an add-on but as a foundational component of modern SCLC management—one that addresses the full spectrum of chemotherapy-induced myelosuppression from the outset of treatment.

Register today to join a Case-Based Roundtable near you.

REFERENCE

1. Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449-460. doi:10.1016/j.cllc.2021.03.010